As none of the participations of the three joint venture partners Evergreen, Q-Cells and REC in Sovello exceeded 50 %, at or after the date of notification of aid to Sovello2, the Commission would normally not take their market share into account for the assessment of the compatibility with point 24(a) of the MSF 2002 [The same view was taken in Commission decision N 850/06, aid to Q-Cells.].
135 6. ASSESSMENT OF THE AID › 6.4. Compatibility of the aid with the MSF 2002 provisions › 6.4.3. Compatibility with the rules under point 24 of the MSF 2002 › 6.4.3.4. Point 24(a) of the MSF 2002: market shares, Decision_act (EU) 2009/697
In forcesince 17 Jun 2009